CATEGORIES

Press Release

LATEST

TRENDING

EDITORS CHOICE

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained

52 physicians from across the U.S. selected for the inaugural cohort of the five-year, $100 million initiative Initiative is part of the BMS Foundation commitment...

Corundum Convergence Institute Launches to Catalyze Funding for Research and Innovation in Neuroscience and Systems Biology

New Non-Profit Organization Focuses on Early-Stage Sponsored Research and Venture Philanthropy to Advance Human Health and Well-being

Sheba Medical Center Selects Two Digital Startups for Integration into Newly Expanded Rehabilitation Ward

Israeli Startups Cognishine and Kemtai Will Begin a Pilot Program at Sheba to Provide Physical, Cognitive and Emotional Rehab Support for Injured Soldiers  ARC Innovation...